Anti-Human Coagulation factor III/Tissue Factor Reference Antibody (MRG 004A, RUO) (HB058046)

Name: Anti-Human Coagulation factor III/Tissue Factor Reference Antibody (MRG 004A, RUO)
Brand: abinScience
SKU: HB058046
Price: 326 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HB058046
Descripción	Anti-Human CD142/F3/TF (MRG 004A) (HB058046) is a research-grade recombinant antibody targeting CD142. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG
ID de clon	MRG 004A
Sistema de expresión	Mammalian cells
Objetivo	Tissue factor, CD142, F3, Thromboplastin, Coagulation factor III, TF
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% purity as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	P13726
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4 Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	MRG-004A, MRG004A, MRG004A
Fondo	Tissue factor (CD142/F3) is a ~33 kDa protein. Initiates blood coagulation by forming a complex with circulating factor VII or VIIa. The [TF:VIIa] complex activates factors IX or X by specific limited proteolysis. TF plays a role in normal hemostasis by initiating the cell-surface assembly and propagation of the coagulation protease cascade. CD142 is the therapeutic target of tisotumab vedotin (Tivdak).
Nota	For research use only. Not suitable for clinical or therapeutic use.